Over the past decade, neuroproteomics has shed light on the molecular features of schizophrenia by depicting biological processes involved with its establishment, maintenance and treatment. These studies have also pointed to potential biomarkers applicable to diagnosis and medication monitoring. Edited by a leader in the field of neuroproteomics with contributions from subject experts, this new volume will address recent findings and compile evidence from difference perspectives-such as human samples, animal models, pluripotent stem cell-derived in vitro pre-clinical models-and provide findings to inform the development of innovative future treatment strategies.
This volume will be useful for a broad audience of researchers and professionals, including biologists, neurologists, psychiatrists, analytical chemists, and pharmacists, among others.
Reihe
Auflage
Sprache
Verlagsort
Verlagsgruppe
Springer International Publishing
Zielgruppe
Für Beruf und Forschung
Für höhere Schule und Studium
Illustrationen
1
11 farbige Abbildungen, 1 s/w Abbildung
VIII, 143 p. 12 illus., 11 illus. in color.
Maße
Höhe: 260 mm
Breite: 183 mm
Dicke: 14 mm
Gewicht
ISBN-13
978-3-030-97181-6 (9783030971816)
DOI
10.1007/978-3-030-97182-3
Schweitzer Klassifikation
Daniel Martins-de-Souza holds a PhD in Biochemistry and Molecular Biology and is an Associate Professor of Biochemistry and Head of Proteomics at the University of Campinas (UNICAMP), in Brazil. Daniel´s postdoctoral training was carried out in the Max Planck Institute of Psychiatry in Germany and at the University of Cambridge, in the UK. For two years, Daniel was Principal Investigator in the Dept. of Psychiatry and Psychotherapy of the Ludwig Maximilians University (LMU), just before becoming a Professor. Daniel was elected Affiliated Member of the São Paulo Academy of Sciences in 2019 and Affiliated Member of the Brazilian Academy of Sciences in 2017. He is part of the Editorial Board of seven indexed journals and Associate Editor for npj Schizophrenia. His main expertise is on proteomics and systems biology tools to investigate molecular mechanisms involved in mental disorders.
1. Postmortem brains: what can proteomics tell us about the sources of schizophrenia?.- 2. What can we learn from animal models to study schizophrenia?.- 3. Modeling schizophrenia in vitro: challenges and insights on studying brain cell.- 4. Schizophrenia outside the brain.- 5. Molecular features triggered by antipsychotic medication in brain cells.- 6. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia.- 7. Molecular findings guiding the modulation of the endocannabinoid system as a potential target to treat schizophrenia.- 8. Metabolomics: A powerful tool to understand the schizophrenia biology.- 9. Modulating specific pathways in vitro to understand the synaptic dysfunction of schizophrenia.- 10. Proteomics and schizophrenia: the evolution of a great partnership.
